$BRII-B (02137.HK)$ On October 9, Tseng Bo announced that it...

$BRII-B(02137.HK)$ On October 9, Tseng Bo announced that it submitted an emergency Use Authorization (EUA) application for novel coronavirus neutralizing antibody Bri-196 / Bri-198 to the FDA today. Tengshengbo has become the fourth pharmaceutical company to submit an APPLICATION for EUA, a novel coronavirus neutralizing antibody, to the FDA, following Genoven, Eli Lilly and Vir Bio. The EUA application is based on positive results from the NIH-supported Phase 3 clinical trial of Activ-2, in which the combination therapy of Bri-196 / Bri-198 resulted in a statistically significant 78% reduction in the risk of hospitalization and death in OUTpatients with COVID-19 who were at high risk of clinical progression to severe disease compared to placebo. And it is safer than placebo.